FINWIRES · TerminalLIVE
FINWIRES

カナダ国立銀行、アグニコ・イーグル・マインズの目標株価を引き上げ、投資判断を「アウトパフォーム」に据え置き

By

-- カナダ国立銀行は金曜日、アグニコ・イーグル・マインズ(AEM.TO)の第1四半期決算発表を受け、同社の目標株価を345ドルから350ドルに引き上げ、投資判断を「アウトパフォーム」に据え置いた。 アナリストらは、ホープベイ鉱山とサンニコラス鉱山の技術報告書、第3四半期に発表されるカナディアン・マラティック拡張計画の最新情報、そして2027年に予定されているデツアーレイク地下鉱山とアッパービーバー鉱山の認可取得を背景に、2034年までに430万オンスの生産量増加を見込んでいると述べた。 さらに、フィンランドでの最近の買収により、今後10年間で年間約50万オンスの生産拠点が構築される可能性があり、成長予測はさらに上昇する可能性があると付け加えた。 アグニコは第1四半期末時点で29億1000万米ドルの純現金残高を保有しており、自社株買いプログラムを20億米ドルに拡大する計画だ。アナリストらは、強固な財務体質を背景に、同社は株主へのキャッシュ還元を継続するとともに、有機的成長プロジェクトの開発を加速させることを目指しており、これが年間を通じてさらなる成長促進要因となるだろうと述べた。 「アグニコ・イーグルの第1四半期決算報告に基づき、調整後EBITDAが30億1000万米ドル、調整後EPSが3.41米ドルとなるなど、業績予想を更新しました。売上高の増加と探査コストの削減により、業績はNBCMの予想を上回りました」とアナリストらは述べている。

Price: $249.58, Change: $-5.86, Percent Change: -2.29%

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.

$GEHC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.

$LII